Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoidosis, Pulmonary 1Lymphedema 1HIV Infections 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Cachexia 1Breast Neoplasms, Male 1Breast Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Zidovudine 12Doxorubicin 11Vincristine 9Bleomycin 8Interferon alpha-2 6Methotrexate 5Leucovorin 5Dexamethasone 5Cyclophosphamide 5sargramostim 4Filgrastim 4Cytarabine 4Etoposide 3pomalidomide 2interferon alfa-n1 2Thalidomide 2Rituximab 2Isotretinoin 2Interleukin-2 2Didanosine 2Allopurinol 2tocilizumab 1plerixafor 1liposomal doxorubicin 1interferon gamma-1b 1abemaciclib 1Zalcitabine 1Vinblastine 1Valganciclovir 1Tumor Necrosis Factor-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Acquired Immunodeficiency Syndrome × Pentoxifylline × Clear all
NCT00000646 2021-11-02

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 1 Completed
54 enrolled

Acquired Immunodeficiency Syndrome, Cachexia, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡